-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 6, Langyu Group and Rhythm Pharmaceuticals, Inc.
According to the terms of the agreement, Langyu will first seek regulatory approval and commercialization in China for certain indications, including: POMC biallelic defects, PCSK1 biallelic defects, LEPR biallelic defects, and Bardet-Biedl comprehensive Obesity and binge eating are rare diseases caused by symptoms or Alström syndrome
According to the license agreement, Langyu Group will pay Rythmn an advance payment in cash and stocks as well as milestone payments related to development and commercialization, and pay Rythmn a sales share based on the annual net sales in the Chinese market